Ignite Creation Date:
2025-12-25 @ 12:54 AM
Ignite Modification Date:
2026-01-01 @ 8:09 PM
Study NCT ID:
NCT06010667
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-24
First Post:
2023-08-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sponsor:
Hebei Medical University Fourth Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-08-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-20
First Submit QC Date:
None
Study First Post Date:
2023-08-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-20
Last Update Post Date:
2023-08-24
Last Update Post Date Type:
ACTUAL